circle-image

Short

Trend Resistance

Uptrend Above: 24560

Bull Signal Above: 24700
circle-image

Term

Trend Point Acts

Trend Point: 24460

My PCR: 1.35
599 Range 1099

Bull Market Signal

circle-image

View

Trend Suport

Down Below: 24350

Bear Signal Below: 24200
Short Term View Historic Data

Nifty View Tomorrow: Friday 13 Nov 2026

Day Close

25299
Day High

25384
Day Low

25142
Day Avg

25275
12 Nov 2026
5 SMA

25123
10 SMA

24441
20 SMA

23634
50 SMA

23328
200 SMA

23989
5 EMA

25208
10 EMA

24868
20 EMA

24457
50 EMA

24304
Tomorrow
Resist 2

25540
Resist 1

25420
Mid Point

25300
Suport 1

25180
Suport 2

25060
52W High

26373
52w Low

22179
52w Down

4.07%
52w Up

14.07%
Panic View
Resist 2

25770
Resist 1

25595
Mid Point

25290
Suport 1

24990
Suport 2

24800
5d High

25424
5d Low

24388
10d High

25424
10d Low

22905
Days High & Low 20d High

25424
20d Low

22372
50d High

25424
50d Low

22179
All Avg

24193
FFTH

25079
FTTL

24239
TTTH

24584
TTTL

23567
High & Low Avg TTFH

24407
TFFL

23325
High Avg

24690
Low Avg

23710
All Avg

24200
Nifty Historic Prediction Data

Nifty Last Five Days Moves

SNo. Date Day Close Day High Day Low 5 DMA 10 DMA 20 DMA 50 DMA 200 DMA
1 12 Nov 2026 25299 25384 25142 25123 24441 23634 23328 23989
2 11 Nov 2026 25255 25424 25095 24970 24205 23500 23304 23988
3 09 Nov 2026 25044 25084 24838 24711 23949 23373 23282 23988
4 08 Nov 2026 24986 25131 24985 24464 23720 23239 23263 23991
5 06 Nov 2026 25030 25030 24388 24155 23497 23116 23248 23994
Nifty Historic Data And Moving Avg

Go Back

Morepen Laboratories Limited Amount and percentage of the turnover or revenue or income and net...

Posted: 14 Jan 2025

Morepen Laboratories Limited Amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year The details of turnover and net worth of Medical Devices Business as on March 31, 2024, are mentioned below: b) Date on which the agreement for sale has been entered into Subject to receipt of requisite regulatory and members’approvals, the Board of Directors of the company hasapproved the sale of the Medical Devices Business of the company to Morepen Medtech Limited, a subsidiary company, as going concern on slump sales basis today i.e.January 14, 2025, including authorising the directors/ officers of the Company to enter the Business TransferAgreement (“BTA”) and other related documents to give effect to the transaction. The BTA will be executed in due course and will be informed to the Stock Exchanges separately. c) Expected date of completion of sale/disposal The completion of the slump sale of the Medical Devices Business is expected to be completed on or before September 30, 2025, subject to receipt of requisite regulatory and other approvals and fulfilment of customary conditions precedent and in accordance with the provisions of the BTA. d) Consideration received from such sale/disposal The consideration for such slump sale will be derived on the basis of the report of the independent valuer in respect of Building and Plant & Machinery, net current assets, other non-current assets and liabilities as per the Balance Sheet as on effective date of transfer of Medical Devices Business and will also be in compliance with Rule 11 UAE of Income Tax Rules 1962. e) Brief details of buyers and whether any of the buyers belong to the promoter/ Morepen Medtech Limited, is a public company (subsidiary of Morepen Laboratories Limited), incorporated on January 8, 2025, to carry on the business of medical devices. Morepen Laboratories Limited CIN NO. L24231 HP1984PLC006028 Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com promoter group/ group companies. If yes, details thereof Yes, Morepen Medtech Limited has been incorporated as a subsidiary of the company, with an aggregate shareholding of 20% of the entities belonging to the promoters’ group/ relatives of promoter/ members of promoter group. f) Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”? Yes, the transaction qualifies as a related party transaction and is being conducted on an arm’s length basis. Furthermore, the company will obtain approval from themembers. g) Whether the sale, lease or disposal of the undertaking is outside the Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations. Yes, the transaction is outside the Scheme of Arrangement.In compliance with Regulation 37A of the SEBI Listing Regulations the “Medical Devices Business” being an“undertaking” in terms of the provisions of the Companies Act, 2013, the company will seek the approval of the members of the company. h) Additional disclosures in case of a ‘slump sale’ i. name of the entity(ies) forming part of the slump sale amalgamation/ merger, details in brief such as, size, turnover etc. Seller: Morepen Laboratories Limited Audited financial details as of March 31, 2024: Particulars Turnover (? in Lakh) Percentage Net worth (? in Lakh) Percentage Other Pharmaceutical Business* 1,24,771.66 73.81% 74,363.57 89.12% Medical Devices Business 44,271.59 26.19% 9,078.52 10.88% Total 1,69,043.25 100.00% 83,442.09 100.00% *Consolidated basis. Buyer: Morepen Medtech Limited, a subsidiary of Morepen Laboratories Limited, as incorporated on January 8, 2025, with the paid-up capital of ? 10,00,000/- (Rupees Ten Lakh Only). ii. whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length” Refer point no. (f) above.

Market Bits

"In investing, what is comfortable is rarely profitable." — Robert Arnott

Be prepared to invest in a down market and to "get out" in a soaring market, as per the philosophy of Warren Buffett.